普米克、酮替酚与核酪口服液在小儿咳嗽变异性哮喘中的应用及预后研究  

Apply and prognosis study of pulmicort combined with kotetifen and haachos on cough variability asthma in children

作　　者：张松成 徐学新[2] 

机构地区：[1]河南省南阳市宛城区第三人民医院,河南南阳473001 [2]河南省南阳市中心医院,河南南阳473001

出　　处：《现代中西医结合杂志》2004年第23期3094-3095,共2页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的　探讨普米克、酮替酚与核酪口服液合用在小儿咳嗽变异性哮喘 (CVA)中的临床疗效和预后。方法　将 6 5例CVA患儿随机分为 2组。对照组 32例仅给予止咳、祛痰、抗感染等处理。治疗组 33例给予普米克 (10 0 μg,2次 /d吸入 )、酮替酚 (<3岁者 0 .5mg 2次 /d口服 ;≥ 3岁者 1mg 2次 /d口服 )和核酪口服液 (5mL 2次 /d口服 )。 2组疗程均为 6个月。随访 0 .5～ 3.5a。结果　治疗组在用药 2周有效率方面明显优于对照组 (P <0 .0 1) ,用药 6个月后治疗组平均止咳时间、CVA复发率和CVA转为哮喘发生率明显低于对照组 (P均 <0 .0 1)。结论普米克、酮替酚与核酪口服液合用能明显、有效地控制CVA咳嗽症状 ,并在预防CVA复发和预防CVA转为哮喘方面疗效显著 ,值得临床应用。Objective It is to discuss the clinical curative eff ect and prognosis of pulmicort combined with kotetifen and haachos on cough variability asthma (CV A) in children.Methods Sixty-five children with CVA were randomly divided into t wo groups. 32 c ases in control group were only treated with antitussives, expectorants and anti biotics. 33 cases in treated group were administered inhalation of pulmicort aer osol and oral kotetifen and haachos. Each course of treatment was 6 months in tw o groups. The patients were followed up for 6 months to 3 years and 6 months.Results After two weeks of administration, the effective rate in t reated group w as significantly higher than that in control group (P<0.01). After 6 months of t reatment, the time of cough being controlled, the recurrent rate of CVA and the occurrence of asthma in treated group were significantly lower than those in con trol group (P<0.01).Conclusion Pulmicort combined with kotetifen and haachos can obvio usly and effec tively control cough symptom of CVA, and has significantly curative effect on pr eventing the recurrence of CVA and CVA conversion asthma, so the therapeutics is worth applying on clinic.

关 键 词：普米克 酮替酚 核酪口服液 小儿 咳嗽变异性哮喘 药物治疗 

分 类 号：R725.622.5[医药卫生—儿科] R985[医药卫生—临床医学]